High-density lipoprotein: Quality is more important than quantity!

Abstract

High density lipoproteins (HDLs) are complex lipid carriers which replace their own structures and functions according to different conditions including healthy or pathological status. HDL has substantial roles in reverse cholesterol transport system for regulation of lipid metabolism. Also HDL has many functions such as antiinflammation, antioxidation, antithrombotic and vasodilator actions. However, these functions may be compromised under pathological conditions. Nowadays, it’s known that the function of HDL is more important than it’s dose for preventing against cardiovascular diseases. This review mostly summarizes available information of HDL structure, metabolism and the real information related to the physicochemical changes of HDLs causing their different functions. Also HDLs, that lost their protective functions have been associated with oxidative stress and systemic inflammation diseases.

Keywords

• Antiinflammatory,
• Antioxidant
• Dysfunctional HDL
• High Density Lipoprotein

References

1. 1. Namita RC, Jayanta RC. Sleisenger and Fordtran's Gastrointestinal and Liver Disease.9th Ed. (2010), 2410 p. ISBN:9781416061892
2. 2. Kenneth R, Feingold MD. Introduction to Lipids and Lipoproteins, Comprehensive Free Online Endocrinology Book Endotex (2021), 1-42 p.
3. 3. Elena GC, Soledad LE, Maria EM, Sergio MP. High-density lipoproteins and immune response: A review. Int. J. Biol. Macromol. (2022);195:117–123 https://doi.org/10.1016/j.ijbiomac.2021.12.009
4. 4. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin.Lipidol. (2010);21(3):229–238
5. 5. Ndrepepa G. High-density lipoprotein: a double-edged sword in cardiovascular physiology and pathophysiology. J Lab Precis Med. (2021);6:28 https://dx.doi.org/10.21037/jlpm-21-32
6. 6. Bonizzi A, Piuri G, Corsi F, Cazzola R and Mazzucchelli S. HDL Dysfunctionality: Clinical Relevance of Quality Rather Than Quantity, Biomedicines (2021);9, 729. https://doi.org/10.3390/biomedicines9070729
7. 7. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis.Atherosclerosis(2009);208:3.https://doi.org/10.1016/j.atherosclerosis.2009.05.034
8. 8. Ben-Aicha S, Badimon L, Vilahur G. Advances in HDL: Much More than Lipid Transporters. Int J Mol Sci. (2020);21:732.doi:10.3390/ijms21030732

9. 9. Vuilleumier N, Dayer JM, Eckardstein A, et al. Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins? Swiss Med Wkly (2013); doi: 10.4414/smw.2013.13781.
10. 10. Bayrak T, Bayrak A, Demirpençe E, Kılınç K. Yeni Bir Kardiyovasküler Belirteç Adayı: Paraoksonaz. Hacettepe Tıp Dergisi (2005);36:147-151
11. 11. Wang W, Zhou W, Wang B, Zhu H, Ye L, Feng M. Antioxidant effect of apolipoprotein A-I on high-fat diet-inducednon-alcoholic fatty liver disease in rabbits. Acta Biochim. Biophys. Sin. (2013);45(2): 95–103 doi:10.1093/abbs/gms100.
12. 12. Nazir S, Jankowski V, Bender G, Zewinger S, Rye KA, Vorst van EPC. Interaction between high-density lipoproteins and inflammation:Function matters more than concentration. Adv Drug Deliv Rev. (2020);159; 94–119. doi: 10.1016/j.addr.2020.10.006.
13. 13. Serban MC, Muntean D, Mikhailids DP, Toth PP, Banach M. Dysfunctional HDL: The journey from savior to slayer. Clin Lipidol. (2014);9(1);49–59
14. 14. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest (2011);121:(7);2693-708 doi:10.1172/JCI42946.
15. 15. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest (1991);88:2039-46.
16. 16. Pirillo A, Catapano AL, Norata GD. Biological Consequences of Dysfunctional HDL. Curr Med Chem (2019);26(9);1644–1664.
17. 17. Benjamın J, Ansell MD, The two faces of the ‘good’ cholesterol. Clevel Clın J Med (2007);74(10) 697-705
18. 18. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes proinflammatory during the acute phaseresponse. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest (1995); 96(6), 2758–2767
19. 19. McEneny J, Wade L, Young S, Masson L, Duthie G, et al. Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. J Clin Invest (2013);24(1):163–168
20. 20. Matsuo M. ABCA1 and ABCG1 as potential therapeutic targets for the prevention of atherosclerosis. J Pharmacol Sci (2022);148:197-203 doi.org/10.1016/j.jphs.2021.11.005
21. 21. Kameda T, Horiuchi Y, Shimano S, Yano K, Lai S, Ichimura N, Tohda S, Kurihara Y, Tozuka M and Ohkawa R, Effect of myeloperoxidase oxidation and N-homocysteinylation of high-density lipoprotein on endothelial repair function Biol Chem (2022); 403(3): 265–277 https://doi.org/10.1515/hsz-2021-0247
22. 22. Brites F, Martin M, Guillas I, Kontush A. Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA Clin (2017);19(8):66–77 DOI: 10.1016/j.bbacli.2017.07.002
23. 23. Wang Y, Ji L, Jiang R, Zheng L and Liu D. Oxidized HDL induces the proliferation and migration of vascular smooth muscle cells by promoting the production of ROS. J Atheroscler Thromb (2014);21(3):204-216. doi: 10.5551/jat.19448
24. 24. Hima BG, Veena SR, Kakkar VV. Friend turns foe:transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response. Cholesterol (2011); doi:10.1155/2011/274629
25. 25. Khera AV, Cuchel M, Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Eng J M (2011);364(2):127–135.
26. 26. Patel PJ, Khera AV, Wilensky RL, Rader DJ. Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail. (2013);15:1215–1219.
27. 27. Kim K, Shim D, Lee JS, Zaitsev K, Williams JW, Kim KW et al. Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models. Circ Res (2018);123:(10);1127–1142
28. 28. Ford HZ, Byrne HM and Myerscough MR. A lipid-structured model for macrophage populations in atherosclerotic plaques. J Theor Biol (2019);479, 48–63
29. 29. Bitla A, Naresh S, Sachan A. High-density lipoprotein: Quality versus quantity in type 2 diabetes mellitus. J Clin Sci Res (2019); 8(4); 193-200
30. 30. Cazzola R, Cassani E, Barichella M, Cestaro B. Impaired fluidity and oxidizability of HDL hydrophobic core and amphipathicsurface in dyslipidemic men. Metabolism (2013); 62(7);986–991
31. 31. Yusoff WNW, Bakar NAA, Muid S, Ali AM, Froemming GRA and Nawawi H. Antioxidant activity of high density lipoprotein (HDL) using different in vitro assay, Int J Fundam Appl Sci (2017);9(6S)298-315 doi: 10.4314/jfas.v9i6s.24